Artificial organs are engineered devices designed to replicate the function of a natural organ when the original fails or deteriorates beyond repair. They range from purely mechanical pumps made of metal and plastic to sophisticated bioartificial systems that incorporate living human cells within synthetic scaffolds. The field has expanded well beyond the familiar dialysis machine and pacemaker, now encompassing devices that oxygenate blood, filter toxins through living liver cells, and even restore partial vision through photovoltaic implants placed on the retina.
Three Categories, Not One
Not all artificial organs are built the same way, and the materials involved determine how closely a device can mimic a real organ. Researchers generally sort them into three classes. Mechanical artificial organs are made entirely of non-living materials like plastics and metals. Think of a titanium heart pump or a polymer dialysis membrane. Biomechanical organs combine non-living materials with some living cells, creating a hybrid that can perform a few biological tasks the purely mechanical version cannot. Bioartificial organs go further, integrating living cells into biodegradable scaffolds to replicate not just the mechanical work of an organ but also its metabolic and hormonal functions.1PubMed Central. Bioartificial Organ Manufacturing Technologies
The practical difference matters. A mechanical device can keep blood moving or filter waste, but it typically cannot produce enzymes, regulate hormones, or respond dynamically to the body’s shifting chemistry. That is why the field has been pushing toward bioartificial designs, which aim to restore not just one function of an organ but the full suite of jobs the original performed.
Mechanical Hearts and Blood Pumps
The heart is, at a mechanical level, a pump. That makes it a natural target for engineering replacement, and heart-assist devices are among the most widely used artificial organs today. Left ventricular assist devices, or LVADs, take over the pumping work of the heart’s main chamber. Most current-generation LVADs use continuous-flow designs, meaning they spin a small rotor at high speed to push blood forward in a steady stream rather than in the pulsing rhythm of a natural heartbeat.
This approach works remarkably well at keeping people alive, but it introduces a problem unique to mechanical blood pumps. Blood passes through extremely narrow flow gaps, sometimes as small as 50 to 500 micrometers, at velocities that generate shear stress far above what the body’s vessels normally produce. Natural blood vessels experience shear stress of roughly two to eight pascals. Current LVADs can generate peak shear stress of up to 1,500 pascals. That force damages blood components, breaking down a clotting protein called von Willebrand factor. The result is an acquired bleeding tendency, with gastrointestinal bleeding occurring in roughly 20 to 40 percent of LVAD patients.2PubMed Central. Reinventing the displacement left ventricular assist device in the continuous-flow era
Some newer designs are trying to solve this by returning to pulsatile flow. One approach uses a reciprocating magnetic mechanism to propel blood in rhythmic pulses that more closely resemble a natural heartbeat, potentially reducing the blood damage caused by continuous spinning.3PubMed. Pressures generated within the chambers of the MagScrew TAH: an in vitro study Whether pulsatile designs can match the durability and compact size of continuous-flow pumps remains an open question.
Every current LVAD also requires a cable, called a driveline, that passes through the skin to connect the internal pump to an external power source and controller. These drivelines need 5 to 25 watts of power, and the exit site where the cable pierces the skin is a persistent source of infection, hospital readmissions, and surgical revisions. Wireless power transmission using electromagnetic fields is the leading candidate to eliminate the driveline entirely, though it has not yet reached widespread clinical use.4The Journal of Heart and Lung Transplantation. What is the ideal driveline design for a Left Ventricular Assist Device?
Artificial Kidneys and Dialysis
The kidneys perform an astonishing range of tasks beyond simply filtering blood. They regulate fluid balance, excrete waste, activate vitamin D, produce hormones, and maintain acid-base balance. Standard hemodialysis handles only part of this job. It uses semipermeable membranes to remove small waste molecules and excess water from the blood, and over the past several decades it has become quite effective at clearing those small molecules. But a category of larger waste products, called middle molecules, tends to slip through conventional membranes and accumulate. These retained toxins contribute to cardiovascular disease, anemia, and malnutrition in dialysis patients.5PubMed Central. Effects of Expanded Hemodialysis with Medium Cut-Off Membranes on Maintenance Hemodialysis Patients: A Review
Newer membrane designs, called medium cut-off membranes, allow those middle molecules to pass through while still retaining essential blood proteins. This expanded form of hemodialysis is considered the closest current technology to mimicking natural kidney filtration. Still, no purely mechanical membrane can replicate the kidney’s metabolic and hormonal work.
That gap is what bioartificial kidneys attempt to fill. The concept pairs a standard synthetic hemofilter with a bioreactor cartridge containing roughly a billion human kidney tubule cells. In early clinical testing with critically ill patients, this combination showed signs of real tubule cell activity: the pH of the filtered fluid shifted in the direction expected from active bicarbonate transport, and the breakdown of glutathione by the cells’ enzymes matched patterns seen in healthy kidneys. The device also showed a modest increase in active vitamin D production, a hormonal function that standard dialysis cannot provide at all.6Kidney International. Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure
Animal studies preceding those trials demonstrated that such a device could sustain filtration, metabolic processing, and hormone production continuously for 24 hours in dogs with acute kidney failure.7American Journal of Kidney Diseases. Metabolic replacement of kidney function in uremic animals with a bioartificial kidney containing human cells Separate work has explored making the system wearable by miniaturizing the hollow-fiber modules and pairing them with continuous hemofiltration, though early prototypes achieved only a fraction of the transport rates needed to fully replace kidney tubule function over a full day.8PubMed. Research into the development of a wearable bioartificial kidney with a continuous hemofilter and a bioartificial tubule device using tubular epithelial cells A truly implantable bioartificial kidney remains years away, but the pieces are being assembled.
Membrane Oxygenators as Artificial Lungs
When the lungs fail acutely, as in severe pneumonia or acute respiratory distress syndrome, clinicians can route blood through a membrane oxygenator outside the body. This is the core technology behind extracorporeal membrane oxygenation, or ECMO. The device works by passing blood alongside bundles of hollow fibers through which oxygen flows. Gas exchange happens across the thin fiber walls: oxygen diffuses into the blood while carbon dioxide diffuses out.
The geometry of those fiber bundles turns out to matter a great deal. Research has shown that even when a quarter of the gas-exchange fibers in a perpendicular bundle arrangement are shut off entirely, the device retains 90 percent or more of its oxygen transfer capacity. The closed fibers still contribute by physically mixing the blood flow, bringing more oxygen-depleted red blood cells into contact with the active fibers.9Journal of Membrane Science. Effect of hollow fiber configuration and replacement on the gas exchange performance of artificial membrane lungs This finding is pushing designers to think about fiber layout as a mixing problem, not just a surface-area problem.
Performance varies with design. At a blood flow rate of three liters per minute, one prototype oxygenator using fine silicone hollow fibers achieved oxygen transfer of about 164 milliliters per minute, while a second design with different fiber characteristics reached 257 milliliters per minute at the same flow rate.10IntechOpen. Development of a Membrane Oxygenator for Long-Term ECMO Support Using Fine Silicone Hollow Fiber A healthy adult lung at rest transfers around 250 milliliters of oxygen per minute, so the better prototype approaches natural lung performance under resting conditions. Making these devices durable enough for weeks or months of continuous use, rather than days, is a major engineering target.
Bioartificial Liver Support
The liver is arguably the hardest organ to replace artificially because it performs hundreds of metabolic tasks simultaneously. When the liver fails acutely, several bioartificial liver support systems have been developed to buy time while waiting for a transplant or for the patient’s own liver to recover. These systems generally route the patient’s blood or plasma through a bioreactor containing living liver cells.
The differences between systems come down to which cells they use and how those cells are housed. The HepatAssist device uses cryopreserved pig liver cells attached to tiny carriers inside hollow fiber cartridges. The ELAD system instead uses about 200 grams of a human liver cell line within similar cartridges. The BLSS system takes a similar approach but with 100 grams of primary pig liver cells. The most elaborate design, the Modular Extracorporeal Liver Support system, combines a bioreactor containing 500 to 600 grams of human liver cells with separate detoxification and blood filtration modules, creating a three-dimensional capillary network meant to approximate the liver’s internal architecture.11Annals of Liver Transplantation. Bioartificial liver support for acute liver failure – Section: MATERIAL EXCHANGE IN BIOREACTOR
None of these systems fully replaces liver function. They are designed as bridges, keeping the patient stable for days or weeks. The choice between human and pig cells involves trade-offs: human cell lines can be standardized and stored but may not perform all normal liver functions, while primary pig cells are more metabolically complete but raise concerns about cross-species immune reactions and infection.
The Bioartificial Pancreas
For people with type 1 diabetes, the core problem is that the immune system has destroyed the insulin-producing islet cells in the pancreas. Transplanting donor islets can restore insulin production, but the recipient’s immune system will attack those cells too unless suppressed with drugs that carry their own risks. The bioartificial pancreas tries to solve this by encapsulating islet cells inside a semipermeable barrier. The barrier is designed to let insulin, oxygen, and nutrients pass freely in and out while blocking immune cells and antibodies from reaching the islets.12PubMed Central. Progress and challenges of the bioartificial pancreas
Encapsulation strategies range from coating individual islets in nano-thin layers to housing thousands of them in larger macro-scale devices.13PubMed Central. Encapsulation and Immune Protection for Type 1 Diabetes Cell Therapy Smaller capsules allow faster diffusion of nutrients and insulin, but they are harder to retrieve if something goes wrong. Larger devices are easier to implant and remove but struggle with getting enough oxygen to cells in the center of the capsule. Striking the right balance between immune protection, oxygen delivery, and retrievability has been the central challenge for decades, and no encapsulated islet device has yet achieved long-term insulin independence in large clinical trials.
Restoring Sight with Retinal Implants
Artificial vision is one of the most dramatic frontiers. Retinal prostheses work by electrically stimulating the surviving neurons in the retina when the photoreceptor cells (the rods and cones) have degenerated, as in retinitis pigmentosa. Earlier devices required cables through the wall of the eye to deliver power and data, adding surgical complexity and infection risk. Newer photovoltaic retinal implants take a different approach: they use arrays of tiny silicon photodiodes that convert light directly into electrical stimulation of the inner retinal neurons. Because these implants are fully wireless, they avoid the complications of trans-scleral cabling and are simpler to implant surgically.14PubMed Central. Can bionic eyes restore vision? Breakthroughs, challenges, and future frontiers in ophthalmology
The vision these implants provide is still crude compared to natural sight, typically consisting of patterns of light and dark that allow rudimentary shape detection rather than anything approaching normal visual acuity. But for someone who has been completely blind, even a rough sense of shapes, motion, and doorways can be transformative.
Why the Body Fights Back
Every artificial organ that contacts blood or tissue faces two related biological problems: clotting and immune rejection. The moment blood touches a foreign surface, proteins from the blood stick to it almost instantly. Platelets follow, aggregating on the protein layer and initiating a clotting cascade. This is why blood-contacting devices like LVADs and dialysis membranes require patients to take anticoagulant drugs, which carry their own risk of excessive bleeding.15PubMed Central. Unravelling Surface Modification Strategies for Preventing Medical Device-Induced Thrombosis
Surface modification is the primary engineering response. Coating device surfaces with anticoagulants like heparin, or with water-attracting polymers that create a hydration layer to resist protein attachment, can reduce clot formation and potentially allow lower doses of systemic blood thinners.16Exploration of BioMat-X. Advancements in surface modification strategies of vascular grafts to improve biocompatibility and tissue integration The ideal surface would be one the body cannot distinguish from its own tissue. That goal has driven research into zwitterionic coatings, nitric oxide-releasing surfaces, and other strategies that mimic the chemical behavior of the natural blood vessel lining.
For implanted devices that sit within tissue rather than directly in the bloodstream, the immune system mounts a different kind of response. The body recognizes the implant as foreign and progresses through a cascade of inflammation, starting with protein attachment and acute inflammation, moving into chronic inflammation, and eventually walling off the device in a fibrous capsule.17PubMed Central. Biomimetic optimization of silicone breast implant integration: insights into wound healing and the foreign body response That capsule can interfere with the device’s function, especially for bioartificial organs that depend on free exchange of nutrients and signals between the device and surrounding tissue.
Growing Organs from Scratch
Tissue engineering represents the most ambitious vision for artificial organs: building replacement organs from a patient’s own cells, eliminating the immune mismatch problem entirely. One approach starts with a donor organ, strips it of all living cells using detergents and enzymes (a process called decellularization), and then reseeds the remaining protein scaffold with new cells. Researchers have demonstrated this with a mouse pancreas, using human stem cells from placental tissue to repopulate the empty scaffold and regenerate functional pancreatic tissue.18PubMed Central. Refunctionalization of Decellularized Organ Scaffold of Pancreas by Recellularization: Whole Organ Regeneration into Functional Pancreas
Three-dimensional bioprinting offers another route, building tissues layer by layer using bioinks loaded with living cells. The technology has produced small-scale tissue constructs with basic blood vessel networks, but scaling up to a full organ remains extraordinarily difficult. The two biggest obstacles are structural complexity and component heterogeneity: a real organ contains dozens of cell types arranged in precise three-dimensional patterns, and current printing nozzles struggle to fabricate the smallest capillaries, which are only about 5 to 10 micrometers in diameter.19Smart Materials in Medicine. Recent progress of 3D printed vascularized tissues and organs – Section: 2.1. Heart Without a complete capillary network, printed tissue starves at its core. This vascularization bottleneck is widely regarded as the single biggest barrier to printing transplantable organs.
Genetically Modified Pigs and Xenotransplantation
Rather than building organs from synthetic materials or cell scaffolds, another strategy is to grow them in genetically modified pigs. Pig organs are roughly the right size for humans, and genetic engineering can knock out the pig genes most responsible for triggering human immune rejection while adding human genes that help the organ blend in. In animal studies, pig hearts with certain genetic modifications survived for 945 days after transplant into baboons. Pig kidney grafts with different modifications lasted 499 days in primates. Pig islet cells survived even longer, reaching 950 days.20PubMed Central. Genetically engineered pigs for xenotransplantation: Hopes and challenges
Several pig-to-human transplants have now been performed under compassionate-use protocols, most prominently involving kidneys and hearts. Survival has been measured in weeks to months so far rather than years, but the field is moving fast. Xenotransplantation does not technically produce an “artificial” organ in the engineering sense, but it competes for the same clinical space: providing organs for people who would otherwise die waiting for a human donor.
The Regulatory Gray Zone
One underappreciated obstacle to getting bioartificial organs into clinics is that regulators were not set up to evaluate them. Drug authorities like the FDA and the European Medicines Agency were designed to approve pharmaceutical agents, not complex cell-based devices that are surgically implanted. In Europe, bioartificial organs are likely to be classified alongside other advanced therapy medicinal products, a category built for cell-based therapies. But a bioartificial organ is not a substance that can be injected or infused. It is a complex product, more like a device than a drug, used in a transplant procedure that may itself be experimental.21PubMed Central. Early-Phase Clinical Trials of Bio-Artificial Organ Technology: A Systematic Review of Ethical Issues This classification awkwardness creates uncertainty about which clinical trial rules apply, which safety standards govern manufacturing, and how to define a meaningful endpoint for approval. Purely mechanical devices like LVADs have a clearer regulatory path because they fit established medical device frameworks. Bioartificial hybrids do not fit neatly anywhere.
Living with an Artificial Organ
The physical engineering challenges tend to dominate the conversation, but the psychological experience of living with an artificial or transplanted organ is its own significant reality. Research on transplant recipients has found that body image and the struggle to psychologically integrate a foreign organ are major themes in post-transplant adaptation. Complete or partial denial of the graft is frequently reported.22PubMed. Body image in transplant recipients and living organ donors
Qualitative studies have explored this in depth. Recipients describe the transplanted organ as alien, something “stitched to my body by force,” a presence that burns and feels foreign with every breath. Receiving an organ from someone of a different gender can intensify the feeling of non-ownership. Over time, though, most recipients gradually come to accept the organ as part of themselves. Learning about the donor and simply allowing months to pass both appear to help normalize the presence of something that initially felt deeply wrong.23Iran Journal of Psychiatry and Behavioral Sciences. Psychological Adaptation to Transplanted Organ: A Hermeneutic Phenomenological Study
These psychological dynamics apply somewhat differently to mechanical devices. An LVAD patient lives with the constant hum of a motor in their chest, a driveline exiting their abdomen, and an external battery pack. The device is unmistakably not part of the body, and there is no donor narrative to grapple with. Instead, the psychological burden tends to center on dependence: the awareness that a mechanical failure or a dead battery is an immediate life-threatening emergency. Partners and caregivers often share this vigilance, and the strain on relationships is a recognized clinical concern in LVAD programs. The success of an artificial organ, whether biological or mechanical, is never purely an engineering question. It is also a question of whether a person can live with what the device asks of them.